Login to Your Account


Partnering with patient advocacy organizations is an increasingly attractive avenue to speed drugs for rare indications into clinical development. 

Inmed Pharmaceuticals Ltd., a Canadian-listed start-up mixing cannabinoids and noncannabis elements for the treatment of glaucoma is working to move into the clinic this year and attract the kind of big pharma backers that have rallied to support cannabinoid drugmaker GW Pharmaceuticals plc.

Gene therapy developer Regenxbio Inc. has shored up key IP rights and relationships supporting its preclinical therapies for the rare genetic diseases Hurler and Hunter syndromes, executing two exclusive new license and research agreements with the universities of Pennsylvania and Minnesota. 

More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: